thalidomide has been researched along with Aggressive Systemic Mastocytosis in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Aggressive Systemic Mastocytosis: A form of systemic mastocytosis in which patients have impaired organ functions due to multifocal infiltrates of pathological MAST CELLS in bone marrow, liver, spleen, gastrointestinal tract, or skeletal system. The cytomorphology shows a low to high grade.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We conducted a phase II, multicentre, study to investigate thalidomide in severely symptomatic indolent and aggressive systemic mastocytosis." | 5.17 | Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study. ( Barete, S; Bruneau, J; Canioni, D; Chaby, G; Chandesris, O; Damaj, G; Diouf, M; Dubreuil, P; Durieu, I; Grosbois, B; Gruson, B; Hermine, O; Lanternier, F; Larroche, C; Livideanu, C; Lortholary, O; Marolleau, JP; Sevestre, H, 2013) |
| "Thalidomide seems to be an active drug in advanced SM." | 1.35 | Thalidomide in advanced mastocytosis. ( Bernit, E; Canioni, D; Claisse, JF; Damaj, G; Ghez, D; Harlé, JR; Hermine, O; Schleinitz, N, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gruson, B | 1 |
| Lortholary, O | 1 |
| Canioni, D | 2 |
| Chandesris, O | 1 |
| Lanternier, F | 1 |
| Bruneau, J | 1 |
| Grosbois, B | 1 |
| Livideanu, C | 1 |
| Larroche, C | 1 |
| Durieu, I | 1 |
| Barete, S | 1 |
| Sevestre, H | 1 |
| Diouf, M | 1 |
| Chaby, G | 1 |
| Marolleau, JP | 1 |
| Dubreuil, P | 1 |
| Hermine, O | 2 |
| Damaj, G | 2 |
| Kluin-Nelemans, HC | 1 |
| Ferenc, V | 1 |
| van Doormaal, JJ | 1 |
| van Iperen, C | 1 |
| Peters, WG | 1 |
| Akin, C | 1 |
| Valent, P | 1 |
| Bernit, E | 1 |
| Ghez, D | 1 |
| Claisse, JF | 1 |
| Schleinitz, N | 1 |
| Harlé, JR | 1 |
1 trial available for thalidomide and Aggressive Systemic Mastocytosis
| Article | Year |
|---|---|
Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study.
Topics: Adult; Aged; Bone Marrow; Fatigue; Female; Fever; Gastrointestinal Diseases; Hematologic Diseases; H | 2013 |
2 other studies available for thalidomide and Aggressive Systemic Mastocytosis
| Article | Year |
|---|---|
Lenalidomide therapy in systemic mastocytosis.
Topics: Aged; Female; Humans; Lenalidomide; Male; Mast Cells; Mastocytosis, Systemic; Middle Aged; Multiple | 2009 |
Thalidomide in advanced mastocytosis.
Topics: Aged; Angiogenesis Inhibitors; Bone Marrow Cells; Female; Follow-Up Studies; Humans; Immunosuppressi | 2008 |